NCT03254667

LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis

Prospective, Observational Study Brodalumab Compared With Other Therapies in the Treatment of Adults With Moderate-to-Severe Psoriasis Who Are Candidates for Systemic Therapy or Phototherapy in the Course of Actual Clinical Care

• Status: Enrolling By Invitation
• Phase: —
• Study type: Observational
• Enrollment: 3,500 (estimated)
• Sponsor: Bausch Health Americas, Inc. · Industry
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: —

Summary

Prospective, Observational Study to Assess the Long-Term Safety of Brodalumab Compared with Other Therapies in the Treatment of Adults with Moderate-to-Severe Psoriasis

Detailed description

Prospective, Observational Study to Assess the Long-Term Safety of Brodalumab Compared with Other Therapies in the Treatment of Adults with Moderate-to-Severe Psoriasis Who Are Candidates for Systemic Therapy or Phototherapy in the Course of Actual Clinical Care

Conditions

• Psoriasis

Interventions

Type	Name	Description
BIOLOGICAL	Brodalumab	Brodalumab
DRUG	Comparator Drug (non-biologic IL-17 inhibitors)	Comparator subjects treated with non-biologic IL-17 inhibitors

Timeline

• Start date: 2017-07-25
• Primary completion: 2030-11-10
• Completion: 2031-11-01
• First posted: 2017-08-18
• Last updated: 2025-09-16

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study